Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer

NCT00248287 is registered in ClinicalTrials.gov with US Oncology Research as lead sponsor.

NCT NCT00248287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00248287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
Lead sponsor
US Oncology Research
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 28, 2005
Completion date
December 31, 2026
Enrollment
154 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer